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DOI 10.1016/j.ccr.2011.11.004SUMMARYWe show that imatinib, nilotinib, and dasatinib possess weak off-target activity against RAF and, therefore,
drive paradoxical activation of BRAF and CRAF in a RAS-dependent manner. Critically, because RAS is
activated by BCR-ABL, in drug-resistant chronic myeloid leukemia (CML) cells, RAS activity persists in the
presence of these drugs, driving paradoxical activation of BRAF, CRAF, MEK, and ERK, and leading to an
unexpected dependency on the pathway. Consequently, nilotinib synergizes with MEK inhibitors to kill
drug-resistant CML cells and block tumor growth in mice. Thus, we show that imatinib, nilotinib, and dasa-
tinib drive paradoxical RAF/MEK/ERK pathway activation and have uncovered a synthetic lethal interaction
that can be used to kill drug-resistant CML cells in vitro and in vivo.INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative disease
characterized by myeloid cell expansion in the bone marrow
and blood (O’Dwyer and Druker, 2001). CML accounts for about
15% of adult leukemias, and there are about 5,000 cases each
year in the United States. The largely asymptomatic chronic
phase of CML can last several years and is followed by an accel-
erated phase that indicates disease progression, leading eventu-
ally to a life-threatening acute phase called blast crisis. CML
has complex pathophysiology, but its diagnosis depends on
the presence of the Philadelphia chromosome, a chromosome
9/chromosome 22 translocation that fuses BCR (encoding
breakpoint cluster region) to ABL, which encodes the Abelson
tyrosine kinase. The normal function(s) of BCR is unclear, but
ABL is a cytosolic/nuclear tyrosine kinase that regulates stress
responses, cell growth, and differentiation. Critically, fusion ofSignificance
Acquired drug resistance through BCR-ABL-dependent and B
for the treatment of chronic myeloid leukemia (CML). We sh
they, therefore, drive paradoxical activation of BRAF and CRA
dependency on the pathway, and accordingly, nilotinib and M
in vitro and in vivo. Thus, our study shows that paradoxical ac
responses in CML and provides an intriguing strategy that m
with CML.
CanABL to BCR generates a constitutively active kinase that drives
transformation and leukemogenesis by phosphorylating sub-
strates such as CRKL and STAT5 and activating pathways
such as NF-kB and RAS/RAF/MEK/ERK (Deininger et al., 2000).
The clinical management of CML was revolutionized by imati-
nib, a small molecule ABL inhibitor (Druker et al., 2001). Imatinib
mediates remission in the majority of patients with CML, but
patients can develop resistance through acquired point muta-
tions that block imatinib binding to BCR-ABL. Fortunately,
most imatinib-resistant BCR-ABL mutants are sensitive to niloti-
nib and dasatinib, next-generation drugs that provide vital
second-line treatments (Kantarjian et al., 2010). However,
substitution of threonine 315 in ABL for isoleucine (BCR-
ABLT315I) generates a protein that is resistant to all three drugs,
and this mutant remains a persistent clinical problem for long-
term management of CML. Pan-ABL inhibitors effective against
BCR-ABLT315I are undergoing clinical trials (reviewed in O’HareCR-ABL-independent mechanisms is a persistent problem
ow that some frontline CML drugs are RAF inhibitors, and
F in drug-resistant CML cells. This leads to an unexpected
EK inhibitors mediate synthetic lethal killing of these cells
tivation of BRAF and CRAF can drive unexpected biological
ay prevent the emergence of drug resistance in patients
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Figure 1. Imatinib, Nilotinib, and Dasatinib Acti-
vate RAF, MEK, and ERK in Cells Harboring RAS
Mutations
(A) Western blot for phospho-MEK (ppMEK), MEK, phos-
pho-ERK (ppERK), and ERK2 (loading control) in D04 cells
treated with DMSO (), imatinib, nilotinib, or dasatinib at
the indicated concentrations (mM).
(B) Endogenous BRAF kinase activity in D04 cells treated
with imatinib (I; 5 mM), nilotinib (N; 1 mM), dasatinib (5 mM),
or SB590885 (0.1 mM) for 3 hr. Data represent means of
triplicate measurements with error bars to represent SD.
(C) Endogenous CRAF kinase activity in D04 cells treated
with imatinib (I; 5 mM), nilotinib (N; 1 mM), dasatinib (5 mM),
or SB590885 (0.1 mM) for 3 hr. Data represent means of
triplicate measurements with error bars to represent SD.
(D) Western blot for phospho-MEK (ppMEK), phospho-
ERK (ppERK), and ERK2 (loading control) in SW620, H460,
and Panc-1 cells treated with DMSO (), imatinib
(I; 10 mM), nilotinib (N; 1 mM), or dasatinib (D; 5 mM).
(E) Western blot for NRAS, phospho-MEK (ppMEK),
phospho-ERK (ppERK), and tubulin (loading control) in
D04 cells transfected with nonspecific control (SC) or two
NRAS (NRAS1, NRAS2) siRNAs. The cells were treated
with DMSO () or nilotinib (N; 1 mM) after 48 hr.
(F) Western blot for BRAF, CRAF, phospho-MEK (ppMEK),
phospho-ERK (ppERK), and tubulin (loading control) in
D04 cells transfected with nonspecific control (SC), or two
different BRAF (B1, B2) or two different CRAF (C1, C2)
siRNAs, or combinations thereof. After 72 hr the cells were
treated with DMSO () or nilotinib (N; 1 mM) as indicated.
The dotted line in (E) and (F) shows where discontinuous
sections of the same blot were joined.
See also Figure S1.
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the same protein) are resistant to all current ABL inhibitors and
may represent a future obstacle for CML management (O’Hare
et al., 2009; Eide et al., 2011). Furthermore, patients can develop
resistance that is mediated by BCR-ABL-independent mecha-
nisms, and for these patients treatment options are limited (Bixby
and Talpaz, 2011).
The RAS/RAF/MEK/ERK pathway promotes CML cell survival
(Goga et al., 1995). RAS is a small membrane bound G protein,
and RAF, MEK, and ERK are sequentially activated protein
kinases. There are three RAS genes (HRAS, KRAS, and NRAS)
in humans, and together, they are mutated in about 30% of
human cancers. There are also three RAF genes (ARAF, BRAF,
and CRAF), and BRAF is mutated in about half of melanomas
and at a lower frequency in several other cancers (Wellbrock
et al., 2004). BRAF inhibitors such as vemurafenib (PLX4032,
RG7204) mediate dramatic responses in BRAF mutant mela-
noma patients, but not in BRAF wild-type patients (Flaherty
et al., 2010), validating mutant BRAF as a therapeutic target in
melanoma. However, these drugs also reveal an unexpected
paradox because whereas they inhibit MEK and ERK in cells
expressing oncogenic BRAF, they activate MEK and ERK in cells
expressing oncogenic RAS (Halaban et al., 2010; Hatzivassiliou
et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2010). This
is because in the presence of oncogenic RAS, BRAF inhibition
drives BRAF binding to CRAF, resulting in BRAF acting as a
scaffold to facilitate CRAF hyperactivation by stimulating critical
events such as serine 338 (S338) phosphorylation (Hatzivassiliou
et al., 2010; Heidorn et al., 2010). Paradoxical activation of the716 Cancer Cell 20, 715–727, December 13, 2011 ª2011 Elsevier Incpathway can also be achieved by CRAF inhibition, which drives
CRAF homodimerization in which a drug-bound partner facili-
tates the activation of the drug-free partner through scaffold
functions or conformational changes (Poulikakos et al., 2010).
Thus, under some circumstances RAF inhibitors drive paradox-
ical activation of BRAF and CRAF to accelerate tumorigenesis by
hyperactivating MEK and ERK (Hatzivassiliou et al., 2010; Hei-
dorn et al., 2010).
Here, we investigated if other kinase inhibitors can also drive
paradoxical activation of RAF, MEK, and ERK and investigated
the underlyingmechanisms and potential clinical consequences.
RESULTS
Imatinib, Nilotinib, and Dasatinib Activate RAF, MEK,
and ERK in RAS Mutant Cells
To initiate our study, we treated D04 cells, a melanoma line that
expresses NRASQ61L, with a variety of protein kinase inhibitors
and investigated their effects on the MEK/ERK pathway by
measuring MEK and ERK phosphorylation by western blot. The
majority of compounds tested did not affect MEK or ERK phos-
phorylation (see Figure S1A available online), but surprisingly,
imatinib, nilotinib, and dasatinib stimulated robust MEK and
ERK phosphorylation at concentrations as low as 100 nM (Fig-
ure 1A). Because the peak plasma/serum concentrations of
imatinib, nilotinib, and dasatinib are 5 mM, 4 mM, and 90 nM,
respectively (Weisberg et al., 2007; Druker et al., 2001), these
data show that the drugs activate this pathway at physiologically
relevant concentrations..
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CRAF in D04 cells, albeit much less efficiently than SB590885
(Figures 1B and 1C), a BRAF selective inhibitor (Takle et al.,
2006). We show that imatinib, nilotinib, and dasatinib also acti-
vated MEK and ERK in SW620 (KRASG12V) colorectal carcinoma
cells, Panc1 (KRASG12D) pancreatic carcinoma cells, and H460
(KRASQ61H) lung cancer cells (Figure 1D), but not in BRAFV600E
expressing A2058 or A375P melanoma cells (Figure S1B). We
used RNA interference (RNAi) to show that NRAS depletion
blocked MEK and ERK activation in D04 cells (Figure 1E),
whereas BRAF or CRAF depletion did not (Figure 1F). However,
when BRAF and CRAF were both depleted, MEK and ERK acti-
vation was blocked (Figure 1F).
Imatinib, Nilotinib, and Dasatinib Induce Paradoxical
Activation of the MEK/ERK Pathway by Inhibiting BRAF
and CRAF
The data above show that imatinib, nilotinib, and dasatinib acti-
vate BRAF, CRAF, MEK, and ERK in RAS mutant, but not BRAF
mutant, cells. We, therefore, examined directly if this was driven
by the paradoxical mechanism(s) previously described. First, we
show that although imatinib, nilotinib, and dasatinib activated
BRAF and CRAF in cells (Figures 1B and 1C), they inhibited
BRAF and CRAF in vitro (Figure 2A), their IC50 values determined
to be 1,630, 1,700, and 119 nM, respectively, for BRAF and 515,
745, and 61 nM, respectively, for CRAF.
We next examined if these drugs drove RAF dimerization.
Endogenous CRAF was immunoprecipitated and western
blotted for endogenous BRAF. Imatinib, nilotinib, and dasatinib
all induced robust BRAF binding to CRAF in cells expressing
oncogenic RAS (D04, SW620, H460, and Panc1 cells; Figures
2B and 2C), but not in cells expressing oncogenic BRAF
(A2058 or A375 cells; Figure S2A). Mutations that prevented
BRAF (BRAFR188L) or CRAF (CRAFR89L) binding to RAS (Fabian
et al., 1994) blocked BRAF binding to CRAF (Figures 2D and
2E), confirming that BRAF and CRAF must bind to RAS in order
to dimerize. We also examined if BRAF and CRAF formed homo-
dimers. We expressed myc-epitope or HA-epitope tagged
versions of BRAF or CRAF in D04 cells, immunoprecipitated
the myc-tagged proteins and western blotted for the HA-tagged
proteins, and show that both BRAF and CRAF homodimers were
formed in D04 cells (Figures 2F and 2G).
To test directly if dimer formationwas driven by drug binding to
BRAF or CRAF, we used mutant versions of BRAF and CRAF in
which the so-called gatekeeper residues were substituted with
asparagine (BRAFT529N and CRAFT421N, respectively). We have
previously shown that this mutation blocks drug binding to
BRAF (Whittaker et al., 2010) and confirm here that both
BRAFT529N and CRAFT421N were resistant to imatinib, nilotinib,
and dasatinib (Figure 2A). Critically, BRAFT529N and CRAFT421N
were severely impaired in their ability to form BRAF:CRAF heter-
odimers and BRAF:BRAF or CRAF:CRAF homodimers (Figures
2H–2J; Figure S2B).
Imatinib, Nilotinib, and Dasatinib Induce Paradoxical
MEK/ERK Pathway Activation in Leukemia Cells
Expressing BCR-ABLT315I
The data above show that imatinib, nilotinib, and dasatinib are
weak RAF inhibitors that drive formation of RAF hetero- andCanhomodimers, and stimulate paradoxical activation of BRAF
and CRAF in the presence of activated RAS. Previous studies
have shown that imatinib activates ERK in leukemia cells ex-
pressing imatinib-resistant BCR-ABL (Yu et al., 2002; Suzuki
et al., 2010; Mohi et al., 2004; Chu et al., 2004), so we tested if
this was also driven through paradoxical activation of RAF. For
this we used isogenic clones of murine Ba/F3 pro-B cells whose
growth was driven by either BCR-ABL or BCR-ABLT315I (Golub
et al., 1996). We confirmed that imatinib, nilotinib, and dasatinib
blocked BCR-ABL phosphorylation on tyrosine 245 (Y245) and
CRKL phosphorylation on tyrosine 207 (Y207) in BCR-ABL
Ba/F3 cells (Figure 3A). Furthermore, imatinib, nilotinib, and
dasatinib blocked CRAF activity in these cells (Figure 3B), and
consistent with this, they suppressed CRAF phosphorylation
on S338 and blocked MEK and ERK activity (Figure 3A). In
contrast, in BCR-ABLT315I Ba/F3 cells imatinib, nilotinib, and
dasatinib did not inhibit BCR-ABL or CRKL phosphorylation
(Figure 3C). More importantly, in these cells all three drugs
induced CRAF phosphorylation on S338 (Figure 3C) and acti-
vated CRAF (Figure 3D), MEK, and ERK (Figure 3C). Critically,
we show that whereas imatinib, nilotinib, and dasatinib did not
affect BRAF binding to CRAF in the BCR-ABL cells, they
enhanced BRAF binding to CRAF in BCR-ABLT315I Ba/F3 cells
(Figures 3A and 3C).
We also compared responses in BV173 and BV173R cells.
BV173 cells were derived from a blast crisis CML patient and
express BCR-ABL endogenously, whereas BV173R cells were
selected for imatinib resistance and express BCR-ABLT315I
(Pegoraro et al., 1983; Bartholomeusz et al., 2007). Imatinib,
nilotinib, and dasatinib inhibited BCR-ABL and CRKL phosphor-
ylation in BV173, but not BV173R, cells (Figure 3E). Furthermore,
whereas imatinib, nilotinib, and dasatinib did not induce BRAF
binding to CRAF and inhibited MEK and ERK in BV173 cells,
they induced BRAF binding to CRAF and activated MEK and
ERK in BV173R cells (Figure 3E).
RAS Signaling Is Critical to Paradoxical Activation
of the RAF-ERK Pathway in CML Cells
The results above show that imatinib, nilotinib, and dasatinib
block RAF/MEK/ERK signaling in BCR-ABL cells but induce
unexpected paradoxical activation of this pathway in BCR-
ABLT315I cells. To investigate the mechanism(s) underlying this
difference, we first examined RAS because of its critical role in
RAF activation. Dominant-negative HRAS (HRASS17N) blocked
ERK activation by nilotinib in BCR-ABLT315I Ba/F3 cells (Fig-
ure 4A), and nilotinib blocked RAS activity in BCR-ABL, but not
BCR-ABLT315I, cells (Figure 4B). We also show that imatinib,
nilotinib, and dasatinib did not induce BRAF binding to CRAF
in K562 cells (which express BCR-ABL), but when these cells
expressed HRASG12V, all three drugs induced BRAF binding to
CRAF (Figure 4C). Note that imatinib, nilotinib, and dasatinib
did not increase MEK and ERK phosphorylation in K562 cells
expressing HRASG12V because the pathway is already saturated
by the expression of HRASG12V (Figure 4C). Taken together, we
conclude that RAS plays a critical role in paradoxical MEK/ERK
pathway activation in BCR-ABLT315I expressing cells.
We next examined cell responses to GNF-2, an allosteric
inhibitor of BCR-ABL. As a control we show that GNF-2 blocked
BCR-ABL, CRKL, CRAF, MEK, and ERK phosphorylation incer Cell 20, 715–727, December 13, 2011 ª2011 Elsevier Inc. 717
Figure 2. Imatinib, Nilotinib, and Dasatinib Drive Paradoxical Activation of BRAF and CRAF in RAS Mutant Cells
(A) RAF kinase assays. myc-epitope tagged BRAF, CRAF, BRAFT529N, or CRAFT421N were transiently expressed in COS cells. BRAF and BRAFT529N were
coexpressed with HRASG12V, and CRAF and CRAFT421N were coexpressed with HRASG12V and SRCY527F. The myc-tagged proteins were captured, and their
kinase activity was determined in the presence of imatinib (10 mM), nilotinib (1 mM), or dasatinib (5 mM). The mean of triplicate determinations is shown relative to
DMSO-treated controls (dotted line). Error bars represent the SD.
(B) Western blots for endogenous BRAF andCRAF in CRAF immunoprecipitates (CRAF IP) or cell lysates fromD04 cells treated with DMSO (), imatinib, nilotinib,
or dasatinib at the indicated concentrations.
(C) Western blots for endogenous BRAF and CRAF in CRAF immunoprecipitates (CRAF IP) or cell lysates from SW620, H460, and Panc1 cells treated with DMSO
(), imatinib (I; 10 mM), nilotinib (N; 1 mM), or dasatinib (D; 5 mM).
(D) Western blots for myc-tagged BRAF, endogenous CRAF, or tubulin (loading control) in myc immunoprecipitates (myc IP) or cell lysates from D04 cells
expressing empty vector control (EV), myc-BRAF (BRAF), or myc-BRAFR188L (R188L) and treated with DMSO () or nilotinib (N; 1 mM).
(E) Western blots for myc-tagged CRAF, endogenous BRAF, or tubulin (loading control) in myc immunoprecipitates (myc IP) or cell lysates from D04 cells
expressing empty vector control (EV), myc-CRAF (CRAF), or myc-CRAFR89L (R89L) and treated with DMSO () or nilotinib (N; 1 mM).
(F) Western blots for myc-tagged CRAF, HA-tagged CRAF, or tubulin (loading control) in myc immunoprecipitates (myc IP) or cell lysates from D04 cells
expressing empty vector control (EV), myc-CRAF, or HA-CRAF and treated with DMSO () or nilotinib (+; 1 mM). The dotted line shows where discontinuous
sections of the same blot were joined.
(G) Western blots for myc-tagged BRAF, HA-tagged BRAF, or tubulin (loading control) in myc immunoprecipitates (myc IP) or cell lysates from D04 cells
expressing empty vector control (EV), myc-BRAF, or HA-BRAF and treated with DMSO () or nilotinib (+; 1 mM).
(H) Western blots for FLAG-tagged BRAF or FLAG-tagged BRAFT529N (FLAG-BRAF), endogenous CRAF, phospho-MEK (ppMEK), phospho-ERK (ppERK), and
tubulin (loading control) in CRAF immunoprecipitates (CRAF IP) or cell lysates fromD04 cells expressing empty vector control (EV), FLAG-taggedBRAF (BRAF), or
FLAG-tagged BRAFT529N (T529N) and treated with DMSO (), imatinib (I; 10 mM), or nilotinib (N; 1 mM).
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resistant to GNF-2 by showing that it did not block BCR-ABL
or CRKL phosphorylation in cells expressing this mutant (Fig-
ure 4D). Critically, GNF-2 did not inhibit BRAF activity in vitro
(Figure 4E), and in BCR-ABLT315I Ba/F3 cells it did not induce
BRAF binding to CRAF, did not increase CRAF, MEK, or ERK
phosphorylation (Figure 4D), and did not activate BRAF or
CRAF (Figure 4F). We also performed apposite experiments
with the BRAF selective inhibitors SB590885 and L779450.
Neither agent inhibited BCR-ABL or CRKL phosphorylation in
BCR-ABL Ba/F3 cells, and accordingly, they both stimulated
BRAF binding to CRAF and CRAF, MEK, and ERK phosphoryla-
tion in these cells (Figure 4G). Thus, BCR-ABL inhibitors that do
not inhibit BRAF do not activate the pathway in BCR-ABLT315I
cells, whereas BRAF inhibitors activate the pathway in BCR-
ABL cells.
Taking these data together, we propose the following model.
We posit that imatinib, nilotinib, and dasatinib are weak RAF
inhibitors that drive paradoxical activation of BRAF and CRAF
in the presence of activated RAS. Because RAS is activated
downstream of BCR-ABL (Goga et al., 1995; Suzuki et al.,
2010), when BCR-ABL is inhibited, so is RAS (Figure 4B), and
although BRAF and CRAF are also inhibited, the lack of RAS
activity means that they are not paradoxically activated. In
contrast because BCR-ABLT315I is resistant to these three inhib-
itors, RAS activity persists in the presence of the drugs, and
consequently, they are able to drive paradoxical activation of
BRAF and CRAF.
Nilotinib Synergizes with MEK Inhibition to Induce
Synthetic Lethality in Drug-Resistant CML Cells In Vitro
We next investigated how paradoxical MEK/ERK pathway acti-
vation affected the growth of leukemia cells expressing BCR-
ABLT315I. As mentioned, imatinib, nilotinib, and dasatinib reach
concentrations of 5 mM, 4 mM, and 90 nM, respectively, in
patient plasma (Weisberg et al., 2007; Druker et al., 2001). We,
therefore, examined the effects of imatinib and nilotinib at 3
and 1 mM, respectively, but because dasatinib only activated
the RAF/MEK/ERK pathway at concentrations above 1 mM, we
did not further examine the effects of this drug. As expected,
BCR-ABL Ba/F3 cells were sensitive to imatinib and nilotinib,
whereas BCR-ABLT315I Ba/F3 cells were resistant (Figure 5A).
The MEK inhibitor PD184352 did not inhibit the growth of BCR-
ABL or BCR-ABLT315I Ba/F3 cells, and PD184352 did not syner-
gize with imatinib, to inhibit the growth of BCR-ABLT315I Ba/F3
cells (Figure 5A). Importantly, whereas PD184352 and nilotinib
did not synergize to inhibit the growth of the BCR-ABL Ba/F3
cells, they synergized to inhibit the growth of BCR-ABLT315I
Ba/F3 cells (Figure 5A).
These responses were accompanied by apposite responses
in apoptosis. Thus, imatinib and nilotinib induced apoptosis in
BCR-ABL, but not in BCR-ABLT315I Ba/F3, cells (Figure 5B;
Figure S3A). PD184352 did not induce apoptosis in either line(I) Western blots for HA-tagged BRAF (HA-BRAF), myc-tagged BRAF (myc-BRAF
from D04 cells expressing myc-BRAF, myc-BRAFT529N (myc-T529N), or HA-BRA
(J) Western blots for myc-tagged CRAF (myc-CRAF), FLAG-tagged CRAF (FLAG-
lysates from D04 cells expressing myc-CRAF, FLAG-CRAF, or FLAG-CRAFT421N
See also Figure S2.
Can(Figure 5B; Figure S3A), and whereas it did not synergize with
imatinib, it did synergize with nilotinib to induce apoptosis in
BCR-ABLT315I cells (Figure 5B; Figure S3A). We observed
similar responses in BV173 and BV173R cells. Imatinib and nilo-
tinib inhibited cell proliferation and induced apoptosis in BV173
cells, but not BV173R cells (Figure 5C; Figure S3B). PD184352
did not inhibit cell proliferation or induce apoptosis in either
line, and whereas it synergized with nilotinib to inhibit cell prolif-
eration and induce apoptosis in BV173R cells, we saw no such
synergy with imatinib (Figure 5C; Figure S3B).
These data show that paradoxical activation of RAF leads
CML cells to develop an unexpected dependence on MEK/
ERK signaling, such that if MEK is inhibited, proliferation is
inhibited and apoptosis induced. We support this model by
showing that PD184352 synergized with the BRAF inhibitors
SB590885 and L779450 to inhibit the growth of BCR-ABL
Ba/F3 cells (Figure 5D), whereas GNF-2 did not synergize with
PD184352 to inhibit the growth of BCR-ABLT315I Ba/F3 cells
(Figure 5E). Thus, BRAF inhibitors that did not inhibit BCR-ABL
were able to drive paradoxical activation of RAF and synergy
with MEK inhibitors to kill cells expressing BCR-ABL. Further-
more, GNF-2, which did not drive paradoxical activation of
RAF, did not synergize with MEK to kill BCR-ABLT315I Ba/F3
cells.
We further show that the pan-RAF inhibitors sorafenib and
RAF265 did not inhibit BCR-ABL or CRKL phosphorylation
in BCR-ABLT315I Ba/F3 cells, and although they induced
BRAF binding to CRAF, they inhibited, rather than activated,
MEK and ERK (Figure 5F). Critically, even in the absence of
PD184352, these agents inhibited proliferation and induced
cell death in cells expressing BCR-ABLT315I (Figures 5G and
5H). In line with our previous conclusions (Hatzivassiliou et al.,
2010; Heidorn et al., 2010), we posit that because sorafenib
and RAF265 are relatively potent pan-RAF inhibitors, they drive
RAF dimerization but also inhibit the RAF proteins in the
complexes that are formed. By simultaneously driving the para-
doxical activation of RAF and inhibiting MEK/ERK signaling,
they, therefore, inhibit proliferation and induce death in CML
cells even in the absence of MEK inhibitors. Note also that the
BRAF inhibitor PLX4720, which did not induce strong binding
of BRAF to CRAF (Hatzivassiliou et al., 2010; Heidorn et al.,
2010), only produced weak synergy with PD184352 to inhibit
cell proliferation of these cells (Figure 5I). These data suggest
that the formation of RAF dimers in the presence of RAF inhibi-
tors is critical to the ability of these agents to synergize with
PD184352 and kill the cells.
Nilotinib Synergizes with MEK Inhibition to Induce
Synthetic Lethality in Cells Expressing Compound
BCR-ABL Mutants
Next, we tested if similar responses occurred in cells expressing
compound BCR-ABL mutants because clinical resistance to
ABL inhibitors is mediated largely by T315I or compound), or tubulin (loading control) in myc immunoprecipitates (myc IP) or cell lysates
F and treated with DMSO (), or nilotinib (N; 1 mM).
CRAF), or tubulin (loading control) in FLAG immunoprecipitates (FLAG IP) or cell
(FLAG-T421N) and treated with DMSO (), or nilotinib (N; 1 mM).
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Figure 3. Imatinib, Nilotinib, and Dasatinib Induce Paradoxical RAF, MEK, and ERK Activation in Cells Expressing BCR-ABLT315I
(A) Western blots for endogenous BRAF, CRAF, pY245 BCR-ABL, BCR-ABL, pY207 CRKL, CRKL, pS338 CRAF, ppMEK, ppERK, and ERK2 (loading control) in
CRAF immunoprecipitates (CRAF IP) and cell lysates from Ba/F3 cells expressing BCR-ABL treated with DMSO (), or the indicated concentrations of imatinib,
nilotinib, and dasatinib.
(B) RAF kinase assays. Endogenous CRAF kinase activity in Ba/F3 cells expressing BCR-ABL treated with imatinib, nilotinib, or dasatinib at the indicated
concentrations (mM). Data represent means of triplicate measurements with error bars to represent SD.
(C) Same as in (A) but with Ba/F3 cells expressing BCR-ABLT315I.
(D) Same as in (B) but with BCR-ABLT315I Ba/F3 cells.
(E) Western blots for endogenous BRAF, CRAF, pY245 BCR-ABL, BCR-ABL, pY207 CRKL, CRKL, ppMEK, ppERK, and ERK2 (loading control) in CRAF
immunoprecipitates (CRAF IP) and cell lysates from BV173 and BV173R cells treated with DMSO () or the indicated concentrations of imatinib, nilotinib, and
dasatinib. The dotted line indicates the joining of two discontinuous sections of the same blot.
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and then nilotinib or dasatinib (Shah et al., 2007). We show
that in Ba/F3 cells expressing BCR-ABLG250E/T315I, BCR-
ABLE255K/T315I, or BCR-ABLE255V/T315I, nilotinib did not inhibit720 Cancer Cell 20, 715–727, December 13, 2011 ª2011 Elsevier IncBCR-ABL or CRKL phosphorylation, and induced BRAF binding
to CRAF as well as MEK and ERK activation (Figure S3D).
Furthermore, whereas nilotinib and PD184352 by themselves
did not affect proliferation of cells expressing these compound.
Figure 4. Active RAS Is Required for Paradoxical Activation of RAF/MEK/ERK Signaling
(A) Graph showing phospho-ERK quantification in BCR-ABLT315I Ba/F3 cells expressing empty vector control (EV) or RASS17N and treated with DMSO () or
nilotinib (N; 1 mM). The data were quantified by western blotting, a representative of which is below the graph and shows phospho-ERK (ppERK), myc-RASS17N,
and tubulin (loading control). The ppERK levels are presented relative to tubulin and were calculated from triplicate determinations with error bars to represent
the SD.
(B) Graph showing RAS-GTP quantification in BCR-ABL and BCR-ABLT315I Ba/F3 cells treated with DMSO () or nilotinib (N; 1 mM, 60 min). The data were
quantified by western blotting, a representative of which is below the graph and shows RAS-GTP and total RAS levels in the extracts. The RAS-GTP levels are
shown relative to total RAS levels and are from triplicate experiments with error bars to represent the SD.
(C) Western blots for endogenous BRAF, CRAF, phospho-MEK (ppMEK), phospho-ERK (ppERK), RAS, and ERK2 (loading control) in CRAF immunoprecipitates
(CRAF IP) and cell lysates from K562 cells expressing an empty vector control () or HRASG12V (+) treated with DMSO, imatinib (10 mM), nilotinib (1 mM), or
dasatinib (5 mM).
(D) Western blots for BRAF, CRAF, pY245 BCR-ABL, BCR-ABL, pY207 CRKL, CRKL, pS338 CRAF, ppMEK, ppERK, and tubulin (loading control) in CRAF
immunoprecipitates (CRAF IP) and cell lysates from BCR-ABL and BCR-ABLT315I Ba/F3 cells treated with GNF-2 at the indicated concentrations.
(E) BRAF kinase assay. myc-epitope tagged BRAF was transiently expressed in COS cells with HRASG12V. myc-BRAF was captured, and its kinase activity was
determined in the presence of various GNF-2 concentrations for 30 min. The results are the mean of triplicate determinations, and error bars represent SD.
(F) BRAF and CRAF kinase assays. Endogenous BRAF and CRAF kinase activities were measured in D04 cells treated with DMSO or GNF-2 (1 mM). The data are
presented relative to DMSO and represent triplicate measurements with error bars to represent SD.
(G) Western blot for endogenous BRAF, CRAF, pY245 BCR-ABL, pY207 CRKL, pS338 CRAF, ppMEK, ppERK, and tubulin (loading control) in CRAF immu-
noprecipitates (CRAF IP) and cell lysates fromBCR-ABLBa/F3 cells treatedwith DMSO, SB590885 (0.3 mM), or L779450 (0.3 mM). The dotted line indicates where
discontinuous sections of the same blot were joined.
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in these cells (Figure 5J).
Nilotinib Synergizes with MEK Inhibition to Induce
Synthetic Lethality in Cells Whose Resistance
Is BCR-ABL Independent
We also tested if similar responses occurred in CML cells whose
resistance was mediated by non-BCR-ABL mechanisms. K562
cells were derived from a patient in terminal blast crisis, and
K562R cells are a clone that is resistant due to overexpression
of the SRC family kinase LYN (Donato et al., 2003). In K562 cellsCannilotinib inhibited BCR-ABL and CRKL phosphorylation, sup-
pressed RAS activity, and inhibited CRAF, MEK, and ERK
phosphorylation (Figures S3E and S3F). Nilotinib also blocked
BCR-ABL andCRKL phosphorylation in K562R cells (Figure S3E)
but, nevertheless, did not inhibit RAS (Figure S3F) and did not
block CRAF, MEK, or ERK phosphorylation (Figure S3E). Niloti-
nib induced apoptosis in K562 cells, but PD184352 did not
kill these cells and did not enhance nilotinib-induced cell death
(Figure 5K). In contrast, nilotinib and PD184352 alone did not
affect the growth of K562R cells, but together, they synergized
to induce death in these cells (Figure 5K).cer Cell 20, 715–727, December 13, 2011 ª2011 Elsevier Inc. 721
Figure 5. PD184352 Synergizes with Nilotinib to
Induce Synthetic Lethality in Cells Expressing
BCR-ABLT315I In Vitro
(A) Cell proliferation was measured in BCR-ABL and BCR-
ABLT315I Ba/F3 cells treated with DMSO, PD184352 (PD;
2 mM), imatinib (I; 3 mM), nilotinib (N; 1 mM), or the indicated
combinations for 4 days. Growth, determined in triplicate,
is expressed as a percentage of the DMSO controls, and
error bars represent SD.
(B) Percentage of apoptotic cells in BCR-ABL and BCR-
ABLT315I Ba/F3 cells treated with DMSO, PD184352 (PD;
2 mM), nilotinib (N; 1 mM), or the indicated combinations for
4 days. Apoptosis was detected by staining cells with
annexin V and propidium iodide. The mean percentage of
apoptotic cells is shown, as determined by triplicate
samples, with error bars representing the SD.
(C) Percentage of apoptosis in BV173 and BV173R cells
treated with DMSO, PD184352 (PD; 0.2 mM), nilotinib
(N; 0.1 mM), or the indicated combinations for 6 days. The
cells were fixed and stained with propidium iodide, and
sub-G1 cells were measured by flow cytometry. The mean
of triplicate samples is shown with error bars representing
the SD.
(D) Cell proliferation was measured in BCR-ABL Ba/F3
cells treated with PD184352 (PD; 2 mM), SB590885 (SB;
0.3 mM), L779450 (L; 0.3 mM), or the indicated combina-
tions for 72 hr. Cell growth determinations in triplicate are
expressed relative to the DMSO control. Error bars
represent the SD.
(E) Cell proliferation was measured in BCR-ABL and BCR-
ABLT315I Ba/F3 cells treated with PD184352 (PD; 2 mM),
GNF-2 (1mM), or the indicated combination for 4 days. Cell
growth determinations in triplicate are expressed relative
to the DMSO control. Error bars represent the SD.
(F) Western blots for endogenous BRAF, CRAF, pY245
BCR-ABL, pY207 CRKL, CRKL, pS338 CRAF, ppMEK,
ppERK, and tubulin (loading control) in CRAF immuno-
precipitates (CRAF IP) and cell lysates from BCR-ABLT315I
Ba/F3 cells treated with the indicated concentrations (uM)
of sorafenib (SF) and RAF265.
(G) Cell proliferation was measured in BCR-ABLT315I
Ba/F3 cells treated with the indicated concentrations of
sorafenib (SF) and RAF265 for 72 hr. Growth, determined
in triplicate, is expressed as a percentage of the DMSO
controls, with error bars representing the SD.
(H) Percentage of apoptotic BV173R cells treated with the
indicated concentrations of sorafenib (SF) and RAF265 for
72 hr. Cells were fixed and stained with propidium iodide,
and sub-G1 cells were measured by flow cytometry. The
mean of triplicate samples is shown, with error bars
representing the SD.
(I) Cell proliferation wasmeasured in BCR-ABL Ba/F3 cells
treated with PD184352 (PD; 2 mM), PLX4720 (PLX; 1 mM),
or the indicated combinations for 72 hr. Growth, deter-
mined in triplicate, is expressed as a percentage of the
DMSO controls, and error bars represent SD.
(J) Cell proliferation was measured in BCR-ABLG250E/T315I,
BCR-ABLE255K/T315I, and BCR-ABLE255V/T315I Ba/F3 cells
treated with DMSO, PD184352 (PD; 2 mM), nilotinib (N;
1 mM), or the indicated combinations for 4 days. Growth,
determined in triplicate, is expressed as a percentage
of the DMSO controls, and error bars represent SD.
(K) Percentage of apoptotic K562 and K562R cells treated
with PD184352 (PD; 1 mM), the indicated concentrations of
nilotinib (N; uM), or combinations of both for 4 days. The cells were fixed and stained with propidium iodide, and sub-G1 cells were measured by flow cytometry.
The mean percentage of apoptotic cells is shown, as determined by triplicate samples, along with error bars representing the SD.
See also Figure S3.
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Figure 6. PD184352 Synergizes with Nilotinib to Inhibit Cell Proliferation of CML Primary Cells and Induce Synthetic Lethality in Cells
Expressing BCR-ABLT315I In Vivo
(A) Cell proliferation was measured in mononuclear cells harboring native BCR-ABL isolated from newly diagnosed patients with CML (n = 2) treated ex vivo with
nilotinib (N; 1 mM), PD184352 (PD; 0.3 mM), or both for 96 hr. All treatment conditions were performed in quadruplicate; values are normalized to those of DMSO-
treated control wells and represent the mean ± SE.
(B) As in (A) but with BCR-ABLT315I expressing mononuclear cells isolated from patients with imatinib-resistant CML (n = 2).
(C) As in (A) but with CD34+ cells from healthy individuals (n = 2).
(D and E) The growth of tumor allografts formed by Ba/F3 cells expressing BCR-ABL (D) or BCR-ABLT315I (E) grown in nudemice is shown. Themice were treated
with vehicle, PD184352 (25 mg/kg), nilotinib (25 mg/kg), or both. The results show mean tumor volumes for groups of six animals, with error bars to represent
the SE.
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Synthetic Lethality in Primary Drug-Resistant CMLCells
We next determined if nilotinib and PD184352 also inhibited the
growth of primary cells frompatients with BCR-ABL-driven CML.
Mononuclear cells derived from blood or bone marrow of
patients with CML harboring native BCR-ABL or BCR-ABLT315I
and from healthy individuals were treated with nilotinib,
PD184352, or both for 96 hr, and cell viability was measured.
Consistent with the cell lines, nilotinib inhibited the proliferation
of cells expressing BCR-ABL from newly diagnosed patients
with CML, and PD184352 did not substantially enhance this
effect (Figure 6A). In contrast, nilotinib and PD184352 alone
did not affect the growth of BCR-ABLT315I cells but synergized
to inhibit growth of these cells (Figure 6B). As a control, we
show that CD34+ hematopoietic cells from healthy individuals
were resistant to all combinations of nilotinib and PD184352
(Figure 6C).
Nilotinib and PD184352 Induce Synthetic Lethality
in Drug-Resistant CML Cells In Vivo
Finally, we tested the implications of our findings in vivo by
examining how the drugs affected the growth of subcutaneously
implanted Ba/F3 allografts expressing BCR-ABL or BCR-CanABLT315I. The growth of BCR-ABL tumors was strongly sup-
pressed by nilotinib, but not by PD184352, and PD184352 did
not enhance the growth-inhibitory activity of nilotinib (Figure 6D).
In contrast, BCR-ABLT315I tumors were insensitive to both niloti-
nib and PD184352, but together, these drugs synergized to
inhibit the growth of these tumors (Figure 6E).
Taking all of these data together, we conclude that nilotinib
and PD184352 induced synthetic lethality in drug-resistant
CML cells both in vitro and in vivo.
DISCUSSION
Building on our previous studies, we tested a panel of drugs for
their ability to activate MEK and ERK in cells expressing onco-
genic RAS. Most of the drugs were ineffective, but imatinib,
nilotinib, and dasatinib activated MEK and ERK in a variety of
lines. Critically, we show that these drugs are weak RAF inhibi-
tors whose binding to BRAF and CRAF drives BRAF:CRAF
heterodimer and BRAF and CRAF homodimer formation, leading
to paradoxical activation of both BRAF and CRAF. We estab-
lished an essential role for RAS in these responses by showing
that its depletion blocked MEK/ERK activation, and if BRAF or
CRAF was unable to bind to RAS, they did not form dimers.cer Cell 20, 715–727, December 13, 2011 ª2011 Elsevier Inc. 723
Figure 7. Model of Paradoxical RAF/MEK/ERK
Activation in Drug-Resistant CMLCells by Nilotinib
(A) Nilotinib binds to and inhibits BCR-ABL, which inhibits
downstream signaling, including RAS. Nilotinib also
inhibits BRAF and CRAF, but because RAS is inactivated,
this is without consequence.
(B) Nilotinib inhibits BRAF and CRAF but not BCR-
ABLT315I. Consequently, RAS remains active and so nilo-
tinib induces the formation of RAF dimers and activation of
the RAF/MEK/ERK survival signal. We posit that these
RAF complexes also activate a MEK/ERK-independent
apoptotic signal, but this is overridden by the dominant
survival signal.
(C) Nilotinib inhibits RAF in the presence of BCR-ABLT315I,
leading to paradoxical activation of RAF/MEK/ERK. MEK
inhibition by PD184352 (PD) blocks the survival signal,
allowing apoptosis to predominate.
(D) Pan-RAF drugs such as sorafenib (SF) and RAF265
inhibit both BRAF and CRAF with high potency. So,
although they induce RAF dimers, they simultaneously
inhibit RAF in these dimers, blocking MEK/ERK signaling,
thereby favoring apoptosis.
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showing that depletion of both was necessary to block MEK
and ERK activation by these drugs. Thus, although they only
inhibit RAF weakly, imatinib, nilotinib, and dasatinib possess
sufficient off-target activity to drive the formation of BRAF:CRAF
dimers and stimulate paradoxical activation of the pathway.
It has previously been shown that RAF inhibitors also drive
paradoxical activation of BRAF and CRAF (Halaban et al.,
2010; Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos
et al., 2010), and our data show that imatinib, nilotinib, and
dasatinib appear to mimic these effects. We, therefore, posit
that like RAF inhibitors (Downward, 2011), imatinib, nilotinib,
and dasatinib bind to monomeric RAF and induce RAF dimeriza-
tion in which one partner is bound to drug, and the other is not.
The drug-bound partner then acts as a scaffold, or induces
a conformational change to facilitate activation of the drug-free
partner.
We extended these observations to show that imatinib, niloti-
nib, and dasatinib drove paradoxical activation of the RAF/
MEK/ERK pathway in drug-resistant leukemia cells. Critically,
we showed that inhibition of BCR-ABL causes RAS inactivation724 Cancer Cell 20, 715–727, December 13, 2011 ª2011 Elsevier Inc.in BCR-ABL expressing, but not BCR-ABLT315I
expressing, cells. We further showed that
dominant-negative RAS blocked MEK/ERK
activation in BCR-ABLT315I cells and that
imatinib, nilotinib, and dasatinib drove RAF
dimerization in BCR-ABL cells when oncogenic
RAS was ectopically introduced. These data
establish that RAS plays a key role in these
responses, and accordingly, we propose the
following model. We posit that BCR-ABL inhibi-
tion leads to RAS inhibition, and so, although
RAF is also inhibited, it is not paradoxically acti-
vated (Figure 7A). In contrast because BCR-
ABLT315I is resistant to imatinib, nilotinib, and
dasatinib, RAS activity persists in the presence
of these drugs, and hence, the off-targetinhibition of RAF leads to its paradoxical pathway activation (Fig-
ure 7B). Thismodel also explains whyBRAF inhibitors drive para-
doxical activation of the pathway in BCR-ABL cells: they do not
inhibit BCR-ABL, so do not inhibit RAS and, hence, can drive
paradoxical activation of RAF. It also explains why BCR-ABL
inhibitors such as GNF-2 do not drive paradoxical activation of
the pathway: although they do not inhibit BCR-ABLT315I and,
therefore, do not inhibit RAS, they are not BRAF/CRAF inhibitors
and so cannot drive their paradoxical activation.
It has been reported that imatinib activates MEK and ERK in
cells expressing imatinib-resistant BCR-ABL (Yu et al., 2002;
Suzuki et al., 2010; Mohi et al., 2004; Chu et al., 2004), and our
studies now provide a mechanistic explanation for those obser-
vations. More importantly, we show that whereas the growth of
the drug-resistant cells was unaffected by nilotinib and
PD184352 in vitro and in vivo, these drugs synergized to inhibit
cell growth and induce apoptosis in vitro, and to suppress tumor
growth in mice. Thus, we show that drug-resistant cells develop
an unexpected dependency on MEK/ERK signaling when the
pathway is paradoxically activated. We, therefore, posit that in
these cells paradoxical activation of this pathway drives both
Cancer Cell
Synthetic Lethality in Resistant Leukemia Cellsa MEK/ERK-dependent antiapoptotic signal and a MEK/ERK-
independent proapoptotic signal (Figure 7B). Under normal
conditions the antiapoptotic signal overcomes the proapoptotic
signal (Figure 7B), but when MEK is inhibited, the proapoptosis
signal predominates (Figure 7C).
It is unclear howMEK inhibition induces apoptosis under these
conditions, but one possibility is that it is driven by the formation
of the RAF dimers. Previous studies have shown that CRAF
opposes cell death in a MEK/ERK-independent manner by
sequestering the proapoptotic kinases ASK1, MST2, ROCK1,
and RIP2 (O’Neill et al., 2004; Navas et al., 1999; Chen et al.,
2001; Piazzolla et al., 2005). We posit that the recruitment of
CRAF into homo- and heterodimers releases these binding
partners, allowing them to induce apoptosis. Our preliminary
experiments failed to establish a clear role for ASK1 andMST2 in
the death of BCR-ABLT315I cells, but the response of these cells
to RAF inhibitors supports our model. We show that SB590885
and L779450 induced robust BRAF binding to CRAF and syner-
gized with PD184352 to induce synthetic lethality (Figures 4G
and 5D). In contrast, PLX4720, which induced weak BRAF
binding to CRAF (Figure S3C), only weakly synergized with the
MEK inhibitor to inhibit cell proliferation (Figure 5I). Furthermore,
although sorafenib and RAF265 induced strong BRAF binding
to CRAF, they simultaneously inhibited MEK signaling and
were thus able to induce cell death without the need of a MEK
inhibitor. It has been proposed that sorafenib induces apoptosis
in imatinib-resistant leukemia cells by targeting multiple kinases
(Rahmani et al., 2007; Kurosu et al., 2009), but our data suggest
that pan-RAF inhibitors such as sorafenib induce apoptosis
because they induce paradoxical activation of RAF and simulta-
neously inhibit MEK/ERK, thereby favoring the proapoptotic
signal (Figure 7D).
Imatinib was approved for first-line treatment of CML over
a decade ago and is generally well tolerated, but 20%–30% of
patients do not achieve complete responses, and acquired
resistance is a persistent clinical problem (Quinta´s-Cardama
et al., 2009). Most imatinib-resistant BCR-ABL mutants remain
sensitive to nilotinib and dasatinib providing vital second-line
treatments (Saglio et al., 2010; Kantarjian et al., 2011), and
both were recently approved as first-line CML drugs. However,
BCR-ABLT315I and the compound mutants that arise following
long-term or sequential drug treatment are resistant to all three
drugs (Shah et al., 2007), and some patients develop resistance
that is mediated by BCR-ABL-independent mechanisms. Thus,
new treatments are still required for relapsed patients, and
agents active against BCR-ABLT315I are undergoing clinical trials
(O’Hare et al., 2011).
We propose that the synthetic lethality we describe could
provide an approach to block the emergence of drug-resistance
in patients. This is based on the observation that BCR-ABL cells
are sensitive to nilotinib alone, whereas the resistant cells are
sensitive to nilotinib plus the MEK inhibitor. Thus, if these drugs
were to be combined, the primary disease would be treated
by nilotinib and the resistant clones by nilotinib plus a MEK
inhibitor. Thus, this combination has the potential to treat both
the bulk disease and prevent the emergence of resistance. Crit-
ically, this synthetic lethality also occurred in K562R cells, where
resistance was mediated by BCR-ABL-independent mecha-
nisms, suggesting that our findings could have wide utility. InCanthis context it is intriguing to note a recent report where acute
lymphoblastic leukemia resistance was shown to be mediated
by EphB4 receptor tyrosine kinase overexpression that led to
constitutive RAS activation and ERK hyperactivation following
imatinib treatment (Suzuki et al., 2010). Importantly, the MEK
inhibitor U0126 synergized with imatinib to inhibit proliferation
of these cells, corroborating our model. Clearly, not all BCR-
ABL drugs will mediate these responses. GNF-2 lacks off-target
RAF activity, and dasatinib, which only inhibits RAF at levels
above those that can be achieved in patients’ blood, would not
be suitable. We wish also to be clear that we are not proposing
BRAF inhibitors for the treatment of CML patients, and indeed,
we show that PLX4720 did not induce robust RAF dimerization
or efficient synthetic lethality.
In summary CML is a heterogeneous disease characterized by
the evolution of drug resistance. We have elaborated an unex-
pected synthetic lethality mediated by paradoxical activation of
RAF in drug-resistant cells. Importantly, this response could
provide approaches to extend clinical responses to nilotinib by
preventing the emergence of the drug-resistant clones.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for detailed protocols.
Reagents
Expression vectors for epitope-tagged BRAF, BRAFT529N, BRAFR188L, CRAF,
CRAFT421N, CRAFR89L, HRASS17N, and HRASG12V have been described
(Marais et al., 1995, 1998). For western blotting the antibodies used were as
follows: rabbit anti-ppMEK1/2 and rabbit anti-phospho-c-Abl (Tyr245),
c-Abl, rabbit anti-phospho-CRKL (Tyr207), and rabbit anti-phospho-CRAF
(Ser338) (Cell Signaling Technology); mouse anti-NRAS (C-20), rabbit anti-
ERK2 (C-14), mouse anti-BRAF (F-7), and Crkl (Santa Cruz Biotechnology);
mouse anti-FLAG, mouse anti-Tubulin, and mouse anti-ppERK1/2 (Sigma-
Aldrich); and mouse anti-CRAF, mouse-anti RAS, and mouse anti-MEK1
(BD Transduction Laboratories). For immunoprecipitation the antibodies
used were rabbit anti-myc (Abcam) and rabbit anti-CRAF (C-20; Santa Cruz
Biotechnology). Imatinib, nilotinib, dasatinib, and sorafenib were from LC
Laboratories (Woburn, MA, USA), GNF-2 from Sigma-Aldrich, SB590885
from Symansis (Timaru, New Zealand), L779450 from Tocris Bioscience
(Ellisville, MO, USA), RAF265 from American Custom Chemicals (San Diego,
CA, USA), and PD184352 was synthesized in house. All drugs were prepared
in DMSO.
Cell Culture Techniques
Human cell lines were cultured in DMEM (A375, A2058, COS-7, Panc1,
SW620, H460, K562) or RPMI (D04, BV173, K562R) supplemented with 10%
fetal bovine serum. Drug treatments were performed for 3 hr, unless otherwise
specified. For RNAi studies D04 cells were transfected with Lipofectamine
(Invitrogen, Paisley, UK) and 10 nM of double-stranded siRNAs. See
Supplemental Experimental Procedures for sequences. Transient and stable
expression of proteins was as described (Wan et al., 2004). For immunoprecip-
itation, lysates were incubated with 5 mg CRAF C-20 or 3 mg myc antibody
(Abcam), captured on Protein G Sepharose 4B beads (Sigma-Aldrich), and
western blotted using standard protocols. FLAG-tagged BRAF was captured
using Anti-FLAG-M2 Agarose beads (Sigma-Aldrich). Coupled RAF assays
were performed as described (Wan et al., 2004). Cell proliferation was deter-
mined using the CellTiter 96 AQueous Non-Radioactive Cell Proliferation
Assay (Promega, Madison, WI, USA), and apoptotic cells were detected using
the FITC Annexin V Apoptosis Detection Kit (BD PharMingen) or propidium
iodide staining of fixed cells followed by fluorescence-activated cell sorting
(FACS) analysis. RAS capture assays were performed as described (Marais
et al., 1998). BRAF and CRAF IC50 determinations were performed using
Z0-LYTE technology (Invitrogen) at 100 mM ATP.cer Cell 20, 715–727, December 13, 2011 ª2011 Elsevier Inc. 725
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Clinical samples were obtained following informed consent and protocol
approval by the Oregon Health & Science University (OHSU) Institutional
Review Board. Mononuclear cells from newly diagnosed and imatinib-resis-
tant CML patients harboring native BCR-ABL or BCR-ABLT315I, respectively
(n = 2/group), were isolated from bone marrow or peripheral blood by Ficoll
centrifugation (GE Healthcare). Normal bone marrow CD34+ cells were
obtained from Lonza. The OHSU Institutional Review Board considers the
use of these materials exempt as human subjects. Cells were distributed in
96-well plates (4 3 104 cells/well) in the presence of PD184352 (0.3 mM) and
nilotinib (1 mM) alone or in combination in serum-free IMDMmedia (Invitrogen)
supplemented with 20% BIT 9500 serum substitute (STEMCELL Technolo-
gies), 40 mg/ml human low-density lipoprotein (Sigma-Aldrich), and 100 mM
b-mercaptoethanol. Cell viability was assessed at 96 hr using the CellTiter
96 AQueous Non-Radioactive Cell Proliferation Assay.
In Vivo Approaches
All procedures involving animals were approved by the Animal Ethics Commit-
tees of the Institute of Cancer Research in accordance with National Home
Office regulations under the Animals (Scientific Procedures) Act 1986 and
according to the guidelines of the Committee of the National Cancer Research
Institute (Workman et al., 2010). Nude mice were injected subcutaneously
with 5 3 106 BCR-ABLT315I Ba/F3 or 2 3 107 BCR-ABL Ba/F3 cells. Tumors
were allowed to establish for 7 days, size matched, and allocated to
groups of six animals. Treatment was by oral gavage daily with vehicle (5%
DMSO, 95% water), 25 mg/kg nilotinib, 25 mg/kg PD184352, or both. Tumor
size was determined by caliper measurements of tumor length, width, and
depth, and volume was calculated as volume = 0.5236 3 length 3 width 3
depth (mm).
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2011.11.004.
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